Skip to content
CancerIndex

Publication

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

Authors not recorded

Clin Cancer Res2006PMID 16638875stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (4)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 4

Curated evidence

Evidence citing this paper (4)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
16638875
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
KIT K642E1
SunitinibGastrointestinal Stromal TumorPredictiveDSupports Sensitivity Response—submitted
EID4145

In an in vitro study, GIST882 cells expressing KIT K642E mutation (endogenous expression) demonstrated sensitivity to sunitinib treatment (IC50<50nM). Sensitivity was determined by assessing KIT auto-… (full text at CIViC)

PMID 16638875 · Prenen et al., 2006 · Open in CIViC

civic
KIT V654A1
SunitinibGastrointestinal Stromal TumorPredictiveBSupports Sensitivity Response3accepted
EID304

In GIST tumor cells and patients harboring KIT V654A mutation, SU11248 is effective for those that are refractory to imatinib.

PMID 16638875 · Prenen et al., 2006 · Open in CIViC

civic
KIT W557_K558del1
SunitinibGastrointestinal Stromal TumorPredictiveDSupports Resistance—submitted
EID4083

In an in vitro study, patient derived tumor cells expressing KIT W557_K558delWK in-frame deletion mutation (endogenous expression) demonstrated sensitivity to sunitinib treatment. Sensitivity was dete… (full text at CIViC)

PMID 16638875 · Prenen et al., 2006 · Open in CIViC

civic
PDGFRA D842V1
SunitinibGastrointestinal Stromal TumorPredictiveDSupports Resistance—submitted
EID4059

In an in vitro study, Ba/F3 cells expressing PDGFRA D842V mutation (overexpression) demonstrated resistance to sunitinib treatment. Sensitivity was determined by assessing PDGFRA auto-phosphorylation … (full text at CIViC)

PMID 16638875 · Prenen et al., 2006 · Open in CIViC

civic